Wiley Blackwell

SHERPA: Unknown

People

  1. Herr
    Herr
  2. Motzer
    Motzer
  3. Brennan
    Brennan
  4. Shah
    Shah
  5. Danishefsky
    Danishefsky
  6. Vickers
    Vickers
  7. Russo
    Russo
  8. Shaha
    Shaha
  9. Eastham
    Eastham
  10. Scardino
    Scardino

Groups

  1. Department of Medicine (1537)
  2. Surgery (1247)
  3. Solid Tumor Oncology Division (893)
  4. Survivorship Research (827)
  5. GSK Faculty (671)
  6. Population Sciences Research Program (628)
  7. Sloan Kettering Institute Faculty (612)
  8. Department of Pathology and Laboratory Medicine (555)
  9. Epidemiology and Biostatistics (494)
  10. Center for Hematologic Malignancies (437)
Search Within
Formats
  1. Journal Article (3530)
  2. Meeting Abstract (684)
  3. Review (200)
  4. Book Section (107)
  5. Conference Paper (94)
  6. Editorial (91)
  7. Research Letter (35)
  8. Guidelines (28)
  9. Correspondence (25)
  10. Miscellaneous (5)
  11. Book Whole (3)
Groups
  1. Department of Medicine (1537)
  2. Surgery (1247)
  3. Solid Tumor Oncology Division (893)
  4. Survivorship Research (827)
  5. GSK Faculty (671)
  6. Population Sciences Research Program (628)

More Groups

People
  1. Harry Herr (92)
  2. Robert Motzer (87)
  3. Murray Brennan (86)
  4. Jatin Shah (77)
  5. Andrew Vickers (74)
  6. Samuel Danishefsky (74)

More People

Years
  1. 2025 (147)
  2. 2024 (192)
  3. 2023 (261)
  4. 2022 (186)
  5. 2021 (221)
  6. 2020 (183)

More Years

Publications
  1. Cancer (1461)
  2. Journal of Surgical Oncology (376)
  3. BJU International (338)
  4. Hematological Oncology (199)
  5. Histopathology (158)
  6. EMBO Journal (132)

More Publications

Results (4802)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I study of CD19‐targeted 19(T2)28z1xx CAR T cells in adult patients with relapsed or refractory diffuse large B‐cell lymphoma
    Meeting Abstract

    Palomba, M. L.; Riviere, I.; Sikder, D. S.; Senechal, B.; Wang, X.; Cathcart, E. R.; Liotta, K.; Li, J.; Sellner, L.; Sadelain, M.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • CNS radiotherapy as bridging prior to CAR T‐cell therapy for hematologic malignancies
    Meeting Abstract

    Cederquist, G.; Hubbeling, H.; Tringale, K.; Shah, G.; Alarcon Tomas, A.; Shouval, R.; Hajj, C.; Fregonese, B.; Lee, J.; Dahi, P. B.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy of subcutaneous epcoritamab versus axi‐cel in R/R DLBCL CAR T‐naive and CAR T‐eligible patients: An indirect comparison
    Meeting Abstract

    Thieblemont, C.; Fox, C. P.; Wang, A.; Sail, K.; Alshreef, A.; Moran, M.; Mutebi, A.; Blaedel, J.; Chirikov, V.; Salles, G.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Long term outcome of peripheral T cell lymphomas: 10y follow‐up analysis of the International Prospective T Cell Project Network
    Meeting Abstract

    Civallero, M.; Advani, R.; Horwitz, S.; Manni, M.; Cabrera, M. E.; Vose, J.; Spina, M.; Hits, F.; Nagler, A.; Montoto, S.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Predictors of response to radiation therapy and of progression to multiple myeloma in patients with solitary bone and extramedullary plasmacytomas
    Meeting Abstract

    Fregonese, B.; Imber, B.; Lee, J.; Zhang, Z.; Toumbacaris, N.; Yahalom, J.; Hajj, C.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Radiation in a new era of multiple myeloma management: Patterns of utilization, clinical, radiologic, and biochemical outcomes, and possible genomic correlates of response
    Meeting Abstract

    Dreyfuss, A. D.; Fregonese, B.; Ma, J.; Reith, S.; Cederquist, G.; Hubbeling, H.; Tringale, K. R.; Wijetunga, N. A.; Usmani, S.; Hajj, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Duvelisib in patients with relapsed/refractory peripheral T‐cell lymphoma from the phase 2 PRIMO Trial Expansion Phase: Outcomes by baseline histology
    Meeting Abstract

    Mehta‐Shah, N.; Jacobsen, E. D.; Zinzani, P. L.; Zain, J.; Mead, M.; Casulo, C.; Gritti, G.; Pinter‐Brown, L.; Izutsu, K.; Waters, S.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Patient‐ versus clinician‐reported symptoms in the POLARIX study
    Meeting Abstract

    Thompson, C. A.; Mehta‐Shah, N.; Flowers, C.; Salles, G.; Tilly, H.; Chua, N.; Casasnovas, R.; Miall, F.; Kim, T. M.; Tsai, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Five‐year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the Phase II L‐MIND study
    Meeting Abstract

    Duell, J.; Abrisqueta, P.; Andre, M.; Augustin, M.; Gaidano, G.; Barca, E. G.; Jurczak, W.; Kalakonda, N.; Liberati, A. M.; Maddocks, K. J.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Five‐year subgroup analysis of tafasitamab + lenalidomide from the phase II L‐MIND study in patients with relapsed or refractory diffuse large B‐cell lymphoma
    Meeting Abstract

    Duell, J.; Abrisqueta, P.; Dreyling, M.; Gaidano, G.; Barca, E. G.; Jurczak, W.; Maddocks, K. J.; Menne, T.; Nagy, Z.; Tournilhac, O.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save